Retrospective and observational study to assess the efficacy of citicoline in elderly patients suffering from stupor related to complex geriatric syndrome

Clinical Interventions in Aging

Volumn 7, Issue , 2012, Pages 113-118

  Putignano, Salvatore ^a   Gareri, Pietro ^a   Castagna, Alberto ^a   Cerqua, Giuliano ^a   Cervera, Pasquale ^a   Cotroneo, Antonino Maria ^a   Fiorillo, Francesco ^a   Grella, Roberto ^a   Lacava, Roberto ^a   Maddonni, Antonio ^a   Marino, Saverio ^a   Pluderi, Alice ^a   Putignano, Daria ^a   Rocca, Filomena ^a  

^a Associazione Geriatri Extraospedalieri Geriatria Italiana Territoriale   (Italy)

Author keywords

Alzheimer's disease; Cerebrovascular disease; Citicoline; Comorbidities; Geriatric syndrome

Indexed keywords

CITICOLINE; NOOTROPIC AGENT;

AGED; ARTICLE; BRAIN ISCHEMIA; CONFUSION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DAILY LIFE ACTIVITY; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FRAIL ELDERLY; FUNCTIONAL STATUS; GERIATRIC DISORDER; HUMAN; HYPERTENSION; INSTRUMENTAL ACTIVITIES OF DAILY LIVING; LAWTON INSTRUMENTAL ACTIVITIES OF DAILY LIVING SCALE; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RANKIN SCALE; RETROSPECTIVE STUDY; STUPOR; UNSPECIFIED SIDE EFFECT; ALZHEIMER DISEASE; CLINICAL TRIAL; HOSPITALIZATION; MULTICENTER STUDY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CONFUSION; CYTIDINE DIPHOSPHATE CHOLINE; FEMALE; HUMANS; MALE; NOOTROPIC AGENTS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STUPOR;

EID: 84867609173     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S29366     Document Type: Article

References (21)

1. Arai H, Ouchi Y, Yokode M, et al. Members of the Subcommittee for Aging. Toward the realization of a better aged society: messages from gerontology and geriatrics. Geriatr Gerontol Int. 2012;12(1):16-22.
2. Alvarez-Sabin J, Roman GC. Citicoline in vascular cognitive impairment and vascular dementia after stroke. Stroke. 2011;42(Suppl 1): S40-S43.
3. Garcia-Cobos R, Frank-Garcia A, Gutierrez-Fernandez M, Diez-Tejedor E. Citicoline, use in cognitive decline: vascular and degenerative. J Neurol Sci. 2010;299(1-2):188-192.
4. Hurtado O, Lizasoain I, Moro MA. Neuroprotection and recovery: recent data at the bench on citicoline. Stroke. 2011;42(Suppl 1):S33-S35.
5. Teather LA, Wurtman RJ. Dietary cytidine (5y)-diphosphocholine supplementation protects against development of memory deficits in aging rats. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(4): 711-717.
6. Secades JJ. Citicoline: pharmacological and clinical review, 2010 update. Rev Neurol. 2011;52 Suppl 2:S1-S62.
7. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;2: CD000269.
8. Zafonte R, Friedewald WT, Lee SM, et al. The citicoline brain injury treatment (COBRIT) trial: design and methods. J Neurotrauma. 2009; 26(12):2207-2216.
9. Caamaño J, Gómez MJ, Franco A, Cacabelos R. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer's disease. Methods Find Exp Clin Pharmacol. 1994;16(3):211-218.
10. Alvarez XA, Mouzo R, Pichel V, et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol. 1999;21(9): 633-644.
11. Secades JJ, Alvarez-Sabín J, Rubio F, Lozano R, Davalos A, Castillo J; Trial Investigators. Citicoline in intracerebral haemorrhage: a doubleblind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc Dis. 2006;21(5-6):380-385.
12. Cho HJ, Kim YJ. Efficacy and safety of oral citicoline in acute ischemic stroke: drug surveillance study in 4,191 cases. Methods Find Exp Clin Pharmacol. 2009;31(3):171-176.
13. Arciniegas DB, Anderson CA, Topkoff J, McAllister TW. Mild traumatic brain injury: a neuropsychiatric approach to diagnosis, evaluation, and treatment. Neuropsychiatr Dis Treat. 2005;1(4):311-327.
14. Cacabelos R, Alvarez XA, Franco-Maside A, Fernandez-Novoa L, Caamano J. Effect of CDP-choline on cognition and immune function in Alzheimer's disease and multi-infarct dementia. Ann N Y Acad Sci. 1993;695:321-323.
15. Cacabelos R, Alvarez XA, Franco-Maside A, Fernandez-Novoa L, Caamano J. Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. Ann N Y Acad Sci. 1996;777:399-403.
16. Rankin J. Cerebral vascular events in patients over the age of 60. II: Prognosis. Scott Med J. 1957;2(5):200-215.
17. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604-607.
18. Sulter G, Steen C, De Keyser J. Use of the Barthel Index and modified Rankin Scale in acute stroke trials. Stroke. 1999;30(8):1538-1541.
19. Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994;25(11):2220-2226.
20. Muir KW, Weir CJ, Murray GD, Povey C, Lees KR. Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke. 1996;27(10):1817-1820.
21. Kasner SE, Chalela JA, Luciano JM, et al. Reliability and validity of estimating the NIH stroke scale score from medical records. Stroke. 1999;30(8):1534-1537.